Takeda Pharmaceutical Company Overview

  • Status
  • Public

  • Employees
  • 49,095

Employees

  • Stock Symbol
  • 4502

Stock Symbol

  • Investments
  • 63

  • Share Price
  • $25.34
  • (As of Friday Closing)

Takeda Pharmaceutical Company General Information

Description

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Contact Information

Website
www.takeda.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Corporate Office
  • 1-1, Nihonbashi-Honcho 2-chome
  • Tokyo, Chuo 103-8668
  • Japan
+81 00-0000-0000

Takeda Pharmaceutical Company Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Takeda Pharmaceutical Company Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.34 $25.48 $25.30 - $33.04 $39.8B 1.57B 3.96M $0.64

Takeda Pharmaceutical Company Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 74,153,014 74,153,014 78,102,878 76,014,887
Revenue 29,509,079 29,509,079 29,749,031 31,768,761
EBITDA 6,564,822 6,564,822 8,501,548 8,933,006
Net Income 997,074 997,074 2,341,651 2,047,822
Total Assets 99,826,841 99,826,841 104,751,518 107,974,090
Total Debt 32,003,648 32,003,648 32,889,031 35,604,125
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Takeda Pharmaceutical Company Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Takeda Pharmaceutical Company‘s full profile, request access.

Request a free trial

Takeda Pharmaceutical Company Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The co
Pharmaceuticals
Tokyo, Japan
49,095 As of 2023
000000000

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000 000000000
Tokyo, Japan
00000 As of 0000
00.000
00000000 00.000

00000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
000000000000000
Tokyo, Japan
00000 As of 0000
0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Takeda Pharmaceutical Company Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Otsuka Holdings Corporation Tokyo, Japan 00000 00.000 00000000 00.000
Eisai Corporation Tokyo, Japan 00000 0000
Daiichi Sankyo Company Corporation Tokyo, Japan 00000 00000000
Astellas Pharma Corporation Tokyo, Japan 00000 00000000
Sandoz Group Corporation Basel, Switzerland 00000 00000000
You’re viewing 5 of 30 competitors. Get the full list »

Takeda Pharmaceutical Company Patents

Takeda Pharmaceutical Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240166746-A1 Dosage regimen of madcam-1 antibody for treatment of non-alcoholic steatohepatitis Pending 22-Nov-2022 00000000000
JP-2024072726-A Patient information analysis method, patient information analysis device, patient information analysis program, and recording medium Pending 16-Nov-2022
US-20240174677-A1 Heterocyclic compound Active 31-Oct-2022 0000000000
US-11987586-B1 Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists Active 31-Oct-2022 0000000000 00
US-20240180968-A1 Adgre2 chimeric receptor nk cell compositions and methods of use Pending 25-Oct-2022 A61K35/17
To view Takeda Pharmaceutical Company’s complete patent history, request access »

Takeda Pharmaceutical Company Executive Team (60)

Name Title Board Seat Contact Info
Christophe Weber Ph.D Representative Director-President, Chief Executive Officer & Board Member
Graeme Martin Chief Executive Officer
Julie Kim President, U.S. Business Unit, U.S. Country Head & Member of Executive Team
Andrew Plump Ph.D Board Member & Director - President, Research & Development
Milano Furuta Chief Financial Officer
You’re viewing 5 of 60 executive team members. Get the full list »

Takeda Pharmaceutical Company Board Members (20)

Name Representing Role Since
000000 00000 00.0 Takeda Pharmaceutical Company Board Member & Director - President, Research & Development 000 0000
0000000000 00000 0 Takeda Pharmaceutical Company Representative Director-President, Chief Executive Officer & Board Member 000 0000
00000 00000000 Takeda Pharmaceutical Company Board Member 000 0000
00000 0000000 Self Board Member & Member of Audit & Supervisory Committee 000 0000
000 00000 Self Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Takeda Pharmaceutical Company Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Takeda Pharmaceutical Company Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Takeda Pharmaceutical Company‘s full profile, request access.

Request a free trial

Takeda Pharmaceutical Company Investments & Acquisitions (63)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ascentage Pharma 20-Jun-2024 0000 0000 Drug Discovery
Joint Venture (Astellas / Sumitomo Mitsui / Takeda) 22-Apr-2024 00000 0000 Drug Discovery 000000000
Orizuru Therapeutics 31-Jan-2024 00000 0000 000.00 Drug Discovery
Crescendo Biologics 24-Jul-2023 00000 0000 0000 Drug Discovery
Cardurion Pharma 12-Jul-2023 Later Stage VC 00000 Biotechnology
You’re viewing 5 of 63 investments and acquisitions. Get the full list »

Takeda Pharmaceutical Company Subsidiaries (9)

Company Name Industry Location Founded
Takeda Digital Ventures Corporate Venture Capital Cambridge, MA 2018
B Positive Plasma Other Healthcare Services Haddonfield, NJ 0000
Takeda Ventures Corporate Venture Capital Cambridge, MA 0000
TiGenix Biotechnology Leuven, Belgium 0000
Takeda (Germany) Distributors/Wholesale Konstanz, Germany 0000
You’re viewing 5 of 9 subsidiaries. Get the full list »

Takeda Pharmaceutical Company ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

21.6 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

0.00

Percentile

To view Takeda Pharmaceutical Company’s complete esg history, request access »

Takeda Pharmaceutical Company Exits (10)

Company Name Exit Date Exit Type Exit Size Status Buyers
Turnstone Biologics 19-Dec-2019 00000 00000 00 00000 Completed
  • 000000 00000000000
Denali Therapeutics 07-Dec-2017 000000000 00000000 00000 Completed
  • 000000 00000000000
Finch Therapeutics 05-Apr-2017 00000 00000 00 0000 Completed
  • 000000 00000000000
PRA Health Sciences KK 15-Feb-2017 00000 0000000 Completed
  • 2 buyers
Mersana Therapeutics 14-Jun-2016 Later Stage VC 000.00 Completed
  • 7 buyers
You’re viewing 5 of 10 exits. Get the full list »

Takeda Pharmaceutical Company FAQs

  • Who is the CEO of Takeda Pharmaceutical Company?

    Christophe Weber Ph.D and Graeme Martin are the CEOs of Takeda Pharmaceutical Company.

  • Where is Takeda Pharmaceutical Company headquartered?

    Takeda Pharmaceutical Company is headquartered in Tokyo, Japan.

  • What is the size of Takeda Pharmaceutical Company?

    Takeda Pharmaceutical Company has 49,095 total employees.

  • What industry is Takeda Pharmaceutical Company in?

    Takeda Pharmaceutical Company’s primary industry is Pharmaceuticals.

  • Is Takeda Pharmaceutical Company a private or public company?

    Takeda Pharmaceutical Company is a Public company.

  • What is Takeda Pharmaceutical Company’s stock symbol?

    The ticker symbol for Takeda Pharmaceutical Company is 4502.

  • What is the current stock price of Takeda Pharmaceutical Company?

    As of 21-Jun-2024 the stock price of Takeda Pharmaceutical Company is $25.34.

  • What is the current market cap of Takeda Pharmaceutical Company?

    The current market capitalization of Takeda Pharmaceutical Company is $39.8B.

  • What is Takeda Pharmaceutical Company’s current revenue?

    The trailing twelve month revenue for Takeda Pharmaceutical Company is $29.5B.

  • Who are Takeda Pharmaceutical Company’s competitors?

    Otsuka Holdings, Eisai, Daiichi Sankyo Company, Astellas Pharma, and Sandoz Group are some of the 30 competitors of Takeda Pharmaceutical Company.

  • What is Takeda Pharmaceutical Company’s annual earnings per share (EPS)?

    Takeda Pharmaceutical Company’s EPS for 12 months was $0.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »